Ocular Toxicity From New Oncology Agents: Safety Review

from TheBrief.Health · host TheBrief.Health

Wider use of targeted cancer drugs and immunotherapies is elevating ocular toxicity risk, requiring early recognition, multidisciplinary coordination, and proactive monitoring to protect vision without compromising cancer control.

Episode metadata supplied by the publisher feed · Published Mar 3, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Ocular Toxicity From New Oncology Agents: Safety Review

0:00 1:33

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of TheBrief.Health?

This episode is 1 minute long.

When was this TheBrief.Health episode published?

This episode was published on March 3, 2026.

Can I download this TheBrief.Health episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!